Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds

Rhea-AI Summary

Aptevo Therapeutics (NASDAQ: APVO) entered into warrant inducement agreements under which certain holders will exercise in full 254,922 existing common stock warrants for cash at a reduced exercise price of $4.03 per share. In exchange, Aptevo will issue new unregistered Inducement Warrants to purchase up to 1,274,610 shares at an exercise price of $4.03, exercisable after required stockholder approval and expiring five years after initial exercise.

Separately, Aptevo agreed to a PIPE financing selling up to 861,708 unregistered shares at $4.03 per share, or pre-funded warrants in lieu of shares, plus Common Warrants to purchase up to 4,308,540 shares at $4.03. Pre-funded warrants are exercisable immediately; Common Warrants become exercisable after stockholder approval and expire five years after initial exercise. Aggregate gross proceeds from these transactions are expected to be about $4.5 million before fees, with closing expected on or about August 13, 2026. Aptevo plans to use net proceeds for working capital.

Positive

• $4.5 million expected gross proceeds from warrant exercises and PIPE
• Immediate cash from exercise of 254,922 existing warrants at $4.03
• PIPE adds up to 861,708 new shares (or pre-funded warrants) at $4.03
• Additional funding capacity via 1,274,610 Inducement Warrants and 4,308,540 Common Warrants

Negative

• Potential dilution from up to 6,444,858 new shares issuable under Inducement and PIPE Warrants plus 861,708 PIPE shares
• Inducement and Common Warrants only exercisable after stockholder approval, adding execution step

News Explained

Reported March 31 cash equaled 164.1 days of first-quarter operating cash use; the proposed $4.5 million is gross and before fees.

As of August 12, 2026, the agreements were announced but not closed; if completed, Aptevo would receive cash while the included shares and warrants, when issued or exercised, would expand share count and reduce existing holders’ percentage ownership.

The PIPE is a private placement—securities sold to selected investors outside a public offering—and the promised registration is for their later resale.

Aptevo reported $14,525,000 of cash and $7,965,000 of first-quarter operating cash outflow at March 31, 2026; that cash equals 164.1 days of the reported quarterly operating cash use.

Sources and calculations

• Aptevo warrant exercise and PIPE announcement (2026-08-12)
• Dilution definition (undated)
• Private placement / PIPE definition (undated)
• Aptevo first-quarter 2026 fundamentals (2026Q1)

• Cash and equivalents vs quarterly operating cash outflow, in days of cash use $14,525,000 / ($7,965,000 / 90) = [object Object]

Market Reaction – APVO

-13.53% $3.58 29.0x vol

15m delay

-13.53% Vs previous close

$3.58 Last Price

$3.50 $4.02 Day Range

$4.33M Market Cap

29.0x Rel. Volume

Following this news, APVO has declined 13.53%, reflecting a significant negative market reaction. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.58. Trading volume is exceptionally heavy at 29.0x the average, suggesting significant selling pressure.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

Aptevo's five recent tracked announcements included four negative 24-hour reactions, including -4.1%...

Analysis

Aptevo's five recent tracked announcements included four negative 24-hour reactions, including -4.1% and -2.42%. That record adds context to this financing, with warrant-related dilution remaining the primary risk to monitor.

Key Figures

Gross proceeds: $4.5 million Existing warrants exercised: 254,922 shares Inducement warrants: 1,274,610 shares +5 more

8 metrics

Gross proceeds $4.5 million Transactions described in the announcement, before fees and expenses

Existing warrants exercised 254,922 shares Cash exercise at $4.03 per share

Inducement warrants 1,274,610 shares New warrants at $4.03 exercise price

PIPE shares 861,708 shares Private placement at $4.03 per share

Common warrants 4,308,540 shares PIPE warrants at $4.03 exercise price

Ownership limitation 4.99% or 9.99% Beneficial ownership limitation for pre-funded warrants

Warrant term Five years Inducement and Common Warrants after initial exercise date

Expected closing August 13, 2026 Subject to customary closing conditions

Historical Context

5 past events · Latest: Jul 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 27	Patent filing	Positive	-4.1%	Filed Nectin-4 x PD-L1 backbone patent for solid-tumor strategy
Jun 30	Research grant	Positive	-2.4%	Received $1.5 million non-dilutive grant supporting APVO451 development
May 28	Leadership appointment	Positive	+3.3%	Appointed Mary J. Janatpour as senior vice president and chief scientific officer
May 27	Strategic partnership	Positive	-1.0%	Launched 50/50 radiopharmaceutical collaboration with Niowave
May 13	Clinical data	Positive	-1.4%	Reported frontline AML clinical benefit and RAINIER development milestones

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Four of the five recent tracked announcements diverged from the stock's headline-positive or strategic news, producing negative 24-hour reactions.

Key Terms

pipe, pre-funded warrants, beneficial ownership limitation, rule 506

4 terms

pipe financial

"Separately, pursuant to a securities purchase agreement, the Company agreed to sell"

A PIPE (private investment in public equity) is a deal in which institutional or accredited investors buy shares or convertible securities directly from a publicly traded company, usually at a discount to the market price. Companies use PIPEs to raise money faster than through a traditional public offering; for existing shareholders they matter because the newly issued shares add to the share count and can dilute ownership.

pre-funded warrants financial

"pre-funded common stock purchase warrants (the "Pre-Funded Warrants")"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

beneficial ownership limitation regulatory

"to comply with a 4.99% or 9.99% beneficial ownership limitation"

A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.

rule 506 regulatory

"and Rule 506 promulgated thereunder, as applicable"

A Securities and Exchange Commission rule that lets companies sell securities without registering them with the SEC when they meet certain conditions, commonly used for private placements. It allows issuers to raise unlimited capital from accredited investors and, in some versions, a small number of knowledgeable non‑accredited investors; one version also permits public advertising if the seller takes steps to verify investor credentials. For investors, it signals a private offering with lighter disclosure and different protections than a public stock sale, similar to buying into a private club rather than a publicly traded marketplace.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced it has entered into warrant inducement letter agreements with certain holders of its existing common warrants (the "Existing Warrants"), pursuant to which such holders have agreed to exercise in full for cash their Existing Warrants to purchase up to an aggregate of 254,922 shares of common stock of the Company ("common stock") at a reduced exercise price of $4.03 per share. In consideration for such cash exercises, the Company will issue new unregistered common stock purchase warrants (the "Inducement Warrants") to purchase up to an aggregate of 1,274,610 shares of common stock at an exercise price of $4.03 per share. The Inducement Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire five years after their initial exercise date. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to effective registration statements on Form S-1 (File No. 333-288061),Form S-1MEF (File No. 333-288134), Form S-3 (File No. 333-284969) and Form S-3 (File No. 333-283983).

Separately, pursuant to a securities purchase agreement, the Company agreed to sell to certain purchasers in a private placement (the "PIPE") up to 861,708 unregistered shares of common stock (the "Shares") at a purchase price of $4.03 per share (or, at a purchaser's election to comply with a 4.99% or 9.99% beneficial ownership limitation, pre-funded common stock purchase warrants (the "Pre-Funded Warrants") to purchase up to 861,708 shares in lieu of such shares), together with common stock purchase warrants (the "Common Warrants") to purchase up to 4,308,540 shares of common stock at an exercise price of $4.03 per share. The Pre-Funded Warrants will be exercisable immediately and will expire upon exercise in full, and the Common Warrants will be exercisable on or after the date on which the Company obtains the required stockholder approval and will expire five years after their initial exercise date (together, the "PIPE Warrants").

The aggregate gross proceeds from the transactions described herein are expected to total approximately $4.5 million, before deducting placement agent fees and expenses.

Roth Capital Partners, LLC is acting as the Company's exclusive placement agent in connection with these transactions.

The transactions are expected to close on or about August 13, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the transactions for working capital purposes.

The Inducement Warrants, the Shares, the Pre-Funded Warrants and the Common Warrants described above were offered in private placement transactions pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "1933 Act"), and Rule 506 promulgated thereunder, as applicable, and, along with the shares of common stock issuable upon exercise of the Inducement Warrants, the Pre-Funded Warrants and the Common Warrants, have not been registered under the 1933 Act and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the Shares and the shares of common stock issuable upon exercise of the Inducement Warrants, the Pre-Funded Warrants and the Common Warrants.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or exemption under the securities laws of any such state or jurisdiction.

About Aptevo Therapeutics

Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company developing novel multispecific immunotherapies for the treatment of cancer. The Company's lead clinical candidate, mipletamig, is currently being evaluated in frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Aptevo's pipeline is generated from its proprietary ADAPTIR^™ and ADAPTIR-FLEX^™ platforms and includes bispecific and trispecific candidates designed to create multiple oncology value drivers across hematologic malignancies and solid tumors. In preclinical development, Aptevo is advancing APVO451, a nectin-4-targeted trispecific immunotherapy candidate for solid tumors and is pursuing strategic opportunities in radiopharmaceutical therapeutics to extend its tumor-targeting expertise into additional cancer treatment approaches. For more information, visit www.aptevotherapeutics.com.

Cautionary Note Regarding Forward-Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, statements regarding the closing of the transactions described herein, the satisfaction of the closing conditions of the transactions, the use of net proceeds from the transactions, and any other statements containing the words "may," "continue to," "believes," "knows," "expects," "optimism," "potential," "designed," "promising," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.

There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; the inability to obtain, maintain or enforce intellectual property protection; further assessment of preliminary or interim data or different results from later studies; adverse events and unanticipated problems; adverse developments in clinical or preclinical development, including unexpected safety issues; constraints in radioisotope availability, manufacturing or supply; and changes in regulatory, social, macroeconomic and political conditions. Additional risks and factors that may affect results are set forth in Aptevo's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025, its subsequent report on Form 10-Q and current reports on Form 8-K. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events or circumstances.

Contact Information

Miriam Weber Miller
VP, Investor Relations & Corporate Communications
Aptevo Therapeutics
Email: IR@apvo.com or Millerm@apvo.com
Phone: 206-859-6628

SOURCE: Aptevo Therapeutics

View the original press release on ACCESS Newswire

FAQ

What did Aptevo Therapeutics (NASDAQ: APVO) announce on August 12, 2026?

Aptevo announced warrant inducement agreements and a PIPE financing expected to generate about $4.5 million in gross proceeds. According to Aptevo, the transactions involve cash exercise of existing warrants, issuance of new Inducement Warrants, and a private placement of shares and additional warrants.

What are the key terms of Aptevo Therapeutics’ $4.5 million PIPE financing for APVO stock?

Aptevo agreed to sell up to 861,708 unregistered shares at $4.03 per share, or pre-funded warrants in lieu of shares, plus Common Warrants for up to 4,308,540 shares at $4.03. According to Aptevo, Common Warrants become exercisable after required stockholder approval.

How many warrants are involved in Aptevo Therapeutics’ August 2026 capital raise?

Aptevo’s transactions include Inducement Warrants for up to 1,274,610 shares and PIPE Common Warrants for up to 4,308,540 shares, all at $4.03. According to Aptevo, 254,922 existing warrants will also be exercised for cash at the same price.

When are Aptevo Therapeutics’ new warrants from the APVO financing exercisable and when do they expire?

According to Aptevo, Inducement Warrants and PIPE Common Warrants become exercisable on or after stockholder approval and expire five years after initial exercise. Pre-funded warrants from the PIPE are exercisable immediately and expire upon full exercise by the holders.

How will Aptevo Therapeutics use the proceeds from the APVO warrant exercises and PIPE?

Aptevo plans to use the net proceeds from the approximately $4.5 million gross financing for working capital purposes. According to Aptevo, this includes general corporate needs supporting its clinical-stage immuno-oncology pipeline and ongoing operations.

Could Aptevo Therapeutics’ August 2026 financing dilute existing APVO shareholders?

The financing could increase Aptevo’s shares outstanding if new shares and warrants are fully exercised. According to Aptevo, the PIPE involves up to 861,708 shares and warrants for millions of additional shares at an exercise price of $4.03.

When is the closing date for Aptevo Therapeutics’ August 2026 PIPE and warrant transactions?

According to Aptevo, the warrant exercises and PIPE financing are expected to close on or about August 13, 2026, subject to satisfaction of customary closing conditions. This timing could affect when the company receives the gross proceeds.